Emergence of Letermovir-resistant HCMV UL56 mutant during rescue treatment in a liver transplant recipient with ganciclovir-resistant infection HCMV: a case report
Open Access
- 23 September 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Infectious Diseases
- Vol. 21 (1), 1-5
- https://doi.org/10.1186/s12879-021-06694-4
Abstract
Human Cytomegalovirus (HCMV) still represents a crucial concern in solid organ transplant recipients (SOTRs) and the use of antiviral therapy are limited by side effects and the selection of viral mutations conferring antiviral drug resistance. Here we reported the case of an HCMV seronegative patient with common variable immunodeficiency (CVID), multiple hepatic adenomatosis, hepatopulmonary syndrome and portal hypertension who received a liver transplant from an HCMV seropositive donor. The patient was treated with Valganciclovir (vGCV) and then IV Ganciclovir (GCV) at 5 week post-transplant for uncontrolled HCMV DNAemia. However, since mutation A594V in UL97 gene conferring resistance to ganciclovir was reported, GCV therapy was interrupted. Due to the high toxicity of Foscarnet (FOS) and Cidofovir (CDV), Letermovir (LMV) monotherapy at the dosage of 480 mg per day was administered, with a gradual viral load reduction. However, a relapse of HCMV DNAemia revealed the presence of mutation C325Y in HCMV UL56 gene conferring resistance to LMV. In conclusion, even if LMV is an effective and favorable safety molecule it might have a lower genetic barrier to resistance. A warning on the use of LMV monotherapy as rescue treatments for HCMV GCV-resistant infections in transplant recipients is warranted.Funding Information
- Fondazione IRCCS Policlinico San Matteo (80207)
This publication has 22 references indexed in Scilit:
- Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphismAntiviral Research, 2014
- Normalizing ELISPOT responses to T-cell counts: A novel approach for quantification of HCMV-specific CD4+ and CD8+ T-cell responses in kidney transplant recipientsJournal of Clinical Virology, 2014
- Letermovir for Cytomegalovirus Prophylaxis in Hematopoietic-Cell TransplantationThe New England Journal of Medicine, 2014
- Geno- and Phenotypic Characterization of Human Cytomegalovirus Mutants SelectedIn Vitroafter Letermovir (AIC246) ExposureAntimicrobial Agents and Chemotherapy, 2014
- Ganciclovir-Resistant Cytomegalovirus Infections among Lung Transplant Recipients Are Associated with Poor Outcomes despite Treatment with Foscarnet-Containing RegimensAntimicrobial Agents and Chemotherapy, 2014
- The Novel Anticytomegalovirus Compound AIC246 (Letermovir) Inhibits Human Cytomegalovirus Replication through a Specific Antiviral Mechanism That Involves the Viral TerminaseJournal of Virology, 2011
- Antiviral Drug Resistance of Human CytomegalovirusClinical Microbiology Reviews, 2010
- Antiviral strategies to combat cytomegalovirus infections in transplant recipientsCurrent Opinion in Pharmacology, 2008
- Human cytomegalovirus double resistance in a donor-positive/recipient-negative lung transplant patient with an impaired CD4-mediated specific immune responseJournal of Antimicrobial Chemotherapy, 2004
- Sequencing of Cytomegalovirus UL97 Gene for Genotypic Antiviral Resistance TestingAntimicrobial Agents and Chemotherapy, 2001